

**Table S1** Univariate and multivariable analyses of distant metastasis-free survival

Variables	UVA			MVA		
	HR	95% CI	P	HR	95% CI	P
Age ( $\geq 66$ vs. $< 66$ years)	0.97	0.65-1.44	0.875			
Sex (male vs. female)	0.92	0.62-1.37	0.686			
KPS ( $> 90$ vs. $\leq 90$ )	0.65	0.42-1.00	0.052			
Disease extent (BRPC vs. LAPC)	1.24	0.83-1.84	0.297			
Tumor location (head vs. other)	1.05	0.70-1.57	0.827			
Induction CT duration ( $\geq 4$ vs. $< 4$ months)	0.53	0.33-0.87	0.011	0.59	0.33-1.04	0.067
Induction CT (FFX vs. GnP)	0.82	0.49-1.34	0.423			
Grade (III vs. I/II)	1.75	1.15-2.70	0.009	1.73	1.09-2.75	0.019
PTV ( $\geq 87$ vs. $< 87$ cm <sup>3</sup> )	1.43	0.95-2.14	0.086			
Baseline CA 19-9 ( $\geq 216$ vs. $< 216$ U/mL)	1.11	0.65-1.87	0.708			
Pre-SBRT CA 19-9 ( $\geq 47$ vs. $< 47$ U/mL)	1.31	0.87-1.97	0.202			
Post-SBRT CA 19-9 ( $\geq 47$ vs. $< 47$ U/mL)	1.27	0.69-2.32	0.443			
$\Delta$ NLR ( $\geq 0.61$ vs. $< 0.61$ )	1.15	0.73-1.80	0.545			
Pre-SBRT counts						
Hct ( $\geq 33.3\%$ vs. $< 33.3\%$ )	0.79	0.53-1.19	0.259			
Platelets ( $\geq 157$ vs. $< 157 \times 1,000/\mu\text{L}$ )	0.92	0.61-1.38	0.683			
ANC ( $\geq 3.7$ vs. $< 3.7$ no./ $\mu\text{L}$ )	1.37	0.91-2.07	0.135			
ALC ( $\geq 1.4$ vs. $< 1.4$ no./ $\mu\text{L}$ )	0.88	0.58-1.32	0.525			
NLR ( $\geq 2.3$ vs. $< 2.3$ )	1.55	1.02-2.37	0.041	1.29	0.82-2.03	0.273
PLR ( $\geq 108.8$ vs. $< 108.8$ )	1.22	0.81-1.84	0.340			
Post-SBRT counts						
Hct ( $\geq 35.9\%$ vs. $< 35.9\%$ )	0.68	0.45-1.04	0.077			
Platelets ( $\geq 153.5$ vs. $< 153.5 \times 1,000/\mu\text{L}$ )	1.13	0.74-1.72	0.570			
ANC ( $\geq 3.0$ vs. $< 3.0$ no./ $\mu\text{L}$ )	1.48	0.93-2.35	0.097			
ALC ( $\geq 0.8$ vs. $< 0.8$ no./ $\mu\text{L}$ )	0.84	0.53-1.33	0.450			
NLR ( $\geq 2.6$ vs. $< 2.6$ )	1.42	0.84-2.40	0.188			
PLR ( $\geq 173.0$ vs. $< 173.0$ )	1.03	0.65-1.62	0.908			

KPS, Karnofsky Performance Status; CA 19-9, carbohydrate antigen 19-9; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CT, chemotherapy; FFX, FOLFIRINOX; GnP; gemcitabine/nab-paclitaxel;  $\Delta$ , change; SBRT, stereotactic body radiation therapy; PTV, planning target volume; Hct, hematocrit; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

**Table S2** Univariate and multivariable analyses of progression-free survival

Variables	UVA			MVA		
	HR	95% CI	P	HR	95% CI	P
Age ( $\geq 66$ vs. $< 66$ years)	0.97	0.67-1.42	0.893			
Sex (male vs. female)	1.05	0.72-1.54	0.788			
KPS ( $> 90$ vs. $\leq 90$ )	1.32	0.86-2.03	0.207			
Disease extent (BRPC vs. LAPC)	1.02	0.69-1.50	0.916			
Tumor location (head vs. other)	1.10	0.75-1.62	0.617			
Induction CT duration ( $\geq 4$ vs. $< 4$ months)	0.53	0.33-0.86	0.011	0.91	0.49-1.69	0.770
Induction CT (FFX vs. GnP)	0.83	0.52-1.34	0.453			
Grade (III vs. I/II)	1.66	1.10-2.51	0.016	1.65	1.04-2.62	0.032
PTV ( $\geq 87$ vs. $< 87$ cm <sup>3</sup> )	1.40	0.95-2.06	0.085			
Baseline CA 19-9 ( $\geq 216$ vs. $< 216$ U/mL)	1.26	0.77-2.05	0.363			
Pre-SBRT CA 19-9 ( $\geq 47$ vs. $< 47$ U/mL)	1.39	0.94-2.06	0.103			
Post-SBRT CA 19-9 ( $\geq 47$ vs. $< 47$ U/mL)	1.44	0.80-2.58	0.221			
$\Delta$ NLR ( $\geq 0.61$ vs. $< 0.61$ )	1.19	0.78-1.84	0.423			
Pre-SBRT counts						
Hct ( $\geq 33.3\%$ vs. $< 33.3\%$ )	0.98	0.66-1.44	0.906			
Platelets ( $\geq 157$ vs. $< 157 \times 1,000/\mu\text{L}$ )	1.03	0.70-1.51	0.887			
ANC ( $\geq 3.7$ vs. $< 3.7$ no./ $\mu\text{L}$ )	1.28	0.86-1.89	0.221			
ALC ( $\geq 1.4$ vs. $< 1.4$ no./ $\mu\text{L}$ )	1.03	0.70-1.52	0.879			
NLR ( $\geq 2.3$ vs. $< 2.3$ )	1.52	1.02-2.28	0.040	1.12	0.71-1.76	0.615
PLR ( $\geq 108.8$ vs. $< 108.8$ )	1.20	0.82-1.78	0.348			
Post-SBRT counts						
Hct ( $\geq 35.9\%$ vs. $< 35.9\%$ )	0.63	0.42-0.95	0.026	0.52	0.33-0.81	0.004
Platelets ( $\geq 153.5$ vs. $< 153.5 \times 1,000/\mu\text{L}$ )	0.96	0.64-1.42	0.824			
ANC ( $\geq 3.0$ vs. $< 3.0$ no./ $\mu\text{L}$ )	1.48	0.95-2.30	0.083			
ALC ( $\geq 0.8$ vs. $< 0.8$ no./ $\mu\text{L}$ )	0.93	0.60-1.45	0.757			
NLR ( $\geq 2.6$ vs. $< 2.6$ )	1.62	0.97-2.70	0.065			
PLR ( $\geq 173.0$ vs. $< 173.0$ )	0.92	0.60-1.43	0.713			

KPS, Karnofsky Performance Status; CA 19-9, carbohydrate antigen 19-9; BRPC, borderline resectable pancreatic cancer; LAPC, locally advanced pancreatic cancer; CT, chemotherapy; FFX, FOLFIRINOX; GnP; gemcitabine/nab-paclitaxel;  $\Delta$ , change; SBRT, stereotactic body radiation therapy; PTV, planning target volume; Hct, hematocrit; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.